D. Szatkowski

发表

α-Melanocyte-Stimulating Hormone Modulates Nitric Oxide Production in Melanocytes1

C. McNeil, A. Graham, P. Manning, 2000 .

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

J. Zaucha, T. Gooley, W. Prejzner, 2005, Bone Marrow Transplantation.

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

P. Sonneveld, A. Waage, N. Abildgaard, 2018, Haematologica.

Imatinib targeted therapy for a patient with chronic eosinophilic leukemia

J. Limon, W. Prejzner, A. Hellmann, 2005 .

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

K. Halaburda, W. Prejzner, A. Hellmann, 2006, Bone Marrow Transplantation.

alpha-melanocyte-stimulating hormone modulates nitric oxide production in melanocytes.

C. McNeil, A. Graham, P. Manning, 2000, The Journal of investigative dermatology.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

U. Mellqvist, P. Sonneveld, B. van der Holt, 2016, Blood.

The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

A. Hellmann, D. Szatkowski, 2014, Acta Haematologica.

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

U. Mellqvist, P. Sonneveld, B. van der Holt, 2019, Haematologica.

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

H. Nahi, A. Waage, M. Hansson, 2020 .

Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment: comments on the article by Smale and Lawson

P. Mielnik, D. Szatkowski, AM Hjelle, 2013, Scandinavian journal of rheumatology.

The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

A. Hellmann, D. Szatkowski, 2014, Acta Haematologica.